BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue …

Nov 14, 2024 · BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of 36% and 82.17%, respectively, for the quarter ended September 2024. ... Inc. (BTAI) Reports Q3 …

CouponFollow Extension

36%
OFF

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue …

6 days from now

Nov 14, 2024 · BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of 36% and 82.17%, respectively, for the quarter ended September 2024. ... Inc. (BTAI) Reports Q3 …

yahoo.com

$0.32
OFF

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue ...

6 days from now

Nov 14, 2024 · BioXcel Therapeutics, Inc. (BTAI Quick Quote BTAI - Free Report) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of …

zacks.com

$0.32
OFF

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue

6 days from now

BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $1.72 per share a year …

msn.com

$13
OFF

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights ...

6 days from now

Nov 15, 2024 · The company reported a net loss of $13.7 million for Q3 2024, although this was an improvement from a $50.5 million loss in Q3 2023. Cost of goods sold increased …

yahoo.com

$0.32
OFF

BioXcel Therapeutics Reports Q3 2024 Financial Results

6 days from now

Nov 15, 2024 · BioXcel Therapeutics reports Q3 EPS (32c), consensus (48c) TipRanks 6d BioXcel Therapeutics GAAP EPS of -$0.32 beats by $0.23, revenue of $0.21M misses by $1.12M

businessinsider.com

$40
OFF

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

6 days from now

Nov 14, 2024 · Cash and cash equivalents totaled $40.4 million as of September 30, 2024. ConferenceCall and Webcast. BioXcel Therapeutics will host a conference call and webcast …

businessinsider.com

$214
OFF

BioXcel Therapeutics Inc Reports Q3 2024 Earnings: Net Revenue A

6 days from now

Net Revenue: Reported $214 thousand for Q3 2024, falling short of the estimated $0.76 million, and down from $341 thousand in Q3 2023.Cost of Goods Sold: Incre. Key Insights from …

gurufocus.com

$214
OFF

BTAI Stock Price | BioXcel Therapeutics Inc. Stock Quote (U.S.: …

6 days from now

4 days ago · BioXcel Therapeutics Inc Reports Q3 2024 Earnings: Net Revenue at $214K, Net Loss Narrows to $13.7M Nov. 14, 2024 at 7:35 a.m. ET on GuruFocus.com BioXcel …

marketwatch.com

$7
OFF

BioXcel Therapeutics Announces Pricing Of $7M Public Offering

6 days from now

1 day ago · BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript. BioXcel announces common stock and warrants offering, no amount given. BioXcel Therapeutics …

seekingalpha.com

$341000
OFF

BioXcel Therapeutics Inc (BTAI) Reports Q3 2023 Financial Results …

6 days from now

Nov 14, 2023 · BioXcel Therapeutics Inc (BTAI) Reports Q3 2023 Financial Results and Strategic Updates ... Net revenue from IGALMI reported at approximately $341,000 for the quarter. ...

yahoo.com

FAQs about BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue … Coupon?

How much did bioxcel Therapeutics (btai) lose?

B ioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $1.72 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 36%. ...

How much cash did bioxcel Therapeutics use in third quarter 2024?

The Company used $16.3 million in operating cash during the third quarter of 2024. Cash and cash equivalents totaled $40.4 million as of September 30, 2024. BioXcel Therapeutics will host a conference call and webcast today, November 14, 2024, at 8:00 a.m. ET to discuss its third quarter 2024 financial results. ...

What is BioXcel Therapeutics (BTAI) doing in 2023?

BioXcel Therapeutics Inc (NASDAQ:BTAI) announced strategic advancements and financial results for the third quarter ended September 30, 2023 in its 8-K filing on November 14, 2023. The company is at the forefront of utilizing artificial intelligence for the development of transformative medicines in neuroscience and immuno-oncology. ...

Is bioxcel Therapeutics a biopharmaceutical company?

NEW HAVEN, Conn., Nov. 14, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced its financial results for the third quarter of 2024. ...

What was the closing price of bioxcel Therapeutics Inc registered SHS?

On Thursday 08/22/2024 the closing price of the BioXcel Therapeutics Inc Registered Shs share was $0.65 on BTT. Compared to the opening price on Thursday 08/22/2024 on BTT of $0.67, this is a drop of 2.47%. BioXcel Therapeutics Inc Registered Shs's market capitalization is $27.14 M by 40.74 M shares outstanding. ...

What is bioxcel Therapeutics Inc registered SS's market capitalization?

BioXcel Therapeutics Inc Registered Shs's market capitalization is $27.14 M by 40.74 M shares outstanding. *The average price target includes all analyst analysis, not just the most recent analysis presented in the chart. Selling, General & Admin. Exp. * Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet ...